Navigation Links
Study identifies double-balloon enteroscopy as cost-effective approach for obscure GI bleeding
Date:11/24/2008

words, associated with the lowest number of quality-adjusted life-years). The arm that had a DBE performed as the initial procedure was more expensive, but was associated with the greatest number of quality-adjusted life-years and the greatest number of patients with cessation of bleeding. All of the other strategies were less effective than the DBE arm and more expensive (with exception of push enteroscopy and the no-therapy arm, which were both less expensive). The no-therapy arm cost $532 and was associated with 0.870 QALYs, whereas the DBE arm cost $2,407 and was associated with 0.956 QALYs, which resulted in an incremental cost-effectiveness ratio of $20,833 per QALY gained. Cost-effectiveness ratios that are less than $50,000 per QALY are considered to be associated with favorable strategies and a reasonable health investment; other examples include $10,000 - $25,000 per QALY for colon or breast cancer screening (figures according to the American Health Quality Association).

Compared with a DBE, an initial CE was more costly and less effective. Based on these results, approximately 86.5 percent of patients would experience cessation of hemorrhage over the course of a year in the DBE arm compared with 76 percent in the CE arm and 59 percent in the no-therapy arm.

The authors concluded that double-balloon enteroscopy, compared to other imaging modalities for obscure GI bleeding, is a cost-effective approach based on the capability of administering therapy during the examination and avoiding the additional cost of the capsule examination. The limitation of these conclusions, however, is the current lack of availability of DBE in many centers. In addition, the rate of complications associated with DBE is currently higher (approximately one percent) compared to standard endoscopic procedures. The study notes that because an initial capsule endoscopy reduced the number of DBE procedures and had fewer associated complications, capsule-directed DBE
'/>"/>

Contact: Anne Brownsey
abrownsey@asge.org
630-570-5635
American Society for Gastrointestinal Endoscopy
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Health study in northern Uganda calls for improved services for internally displaced persons
2. Pregnancy study finds strong association between two antidepressants and heart anomalies
3. Wide-Ranging Study of National News Reveals Health News Comprises Less Than Four Percent of All Coverage
4. Study of ancient and modern plagues finds common features
5. Physicians Anticipate Higher Prescribing Based on JUPITER Study
6. New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
7. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
8. Landmark study defines benefits of early HIV testing and treatment for infected infants
9. Study identifies causes of bone loss in breast cancer survivors
10. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
11. Study Suggests Need for More Aggressive Outpatient Monitoring of Patients Hearts When Cause of Stroke is Unclear
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 2Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 3Health News:Latinos Manage Diabetes With Help From the Community 2Health News:Latinos Manage Diabetes With Help From the Community 3Health News:AIDS care physicians make recommendations to Obama 2Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 2Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 3Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 4Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 5Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 2Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 3Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 4Health News:Kathleen Sebelius Ready to Lead Healthcare Reform in 2009 2
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Exponent Reports Second Quarter 2009 Results 52462 1Exponent Reports Second Quarter 2009 Results 52462 2Exponent Reports Second Quarter 2009 Results 52462 3Exponent Reports Second Quarter 2009 Results 52462 4Exponent Reports Second Quarter 2009 Results 52462 5Exponent Reports Second Quarter 2009 Results 52462 6Exponent Reports Second Quarter 2009 Results 52462 7Exponent Reports Second Quarter 2009 Results 52462 8Exponent Reports Second Quarter 2009 Results 52462 9Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 1Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 2Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 3Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 4Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 5Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 1Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 2Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 3Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 4Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 5Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 6Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 7Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 8Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 9Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 10Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 11Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 12Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 13Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 14Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 15Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 16Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 17